Diabetes
Refine Search
Biotechnology
Intarcia Therapeutics says it has completed its second major close of the Series EE equity financing, and also entered into a relationship with the Bill & Melinda Gates Foundation. 30 December 2016
Generics
A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" cholesterol, despite being treated with statins. 29 December 2016
Pharmaceutical
The European Commission (EC) has authorized the extension of the label for all metformin-containing products for all metformin-containing products for the treatment of type 2 diabetes. 21 December 2016
Generics
Bangladeshi generic drugs company Beximco Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a generic equivalent of Glucophage XR tablets (metformin hydrochloride). 19 December 2016
Biosimilars
A year after its approval by the US Food and Drug Administration, a follow-on version of Sanofi’s blockbuster long acting insulin product Lantus (insulin glargine) has hit the market. 16 December 2016
Pharmaceutical
US pharma major Eli Lilly has moved to provide up to 40% discounts for US users of its insulin products from the start of 2017, as prices rise on the back of soaring insurance rates. 13 December 2016
Pharmaceutical
The US Food and Drug Administration has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. 13 December 2016
Pharmaceutical
As a result of an updated review, the US Food and Drug Administration has concluded that use of the type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. 13 December 2016
Biotechnology
Kadimastem has signed a memorandum of understanding with South Korean company Corestem, for a broad strategic collaboration between the companies. 8 December 2016
Pharmaceutical
Danish diabetes giant Novo Nordisk has pledged to limit its price increases for US patients. 7 December 2016
Pharmaceutical
A New Drug Application has been filed with the US Food and Drug Administration for semaglutide, a glucagon-like peptide-1 (GLP-1) analog administered once-weekly, for the treatment of adults with type 2 diabetes. 5 December 2016
Pharmaceutical
The US Food and Drug Administration on Friday approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. 5 December 2016
Pharmaceutical
New Phase IIIb trial (DUAL VII) results with Xultophy (IDegLira), which was approved by the US Food and Drug Administration last month, were presented today. 2 December 2016
Pharmaceutical
Drugs used for type 2 diabetes mellitus could alleviate symptoms among Alzheimer’s disease patients, or even exert potential disease-modifying effects. 2 December 2016
Pharmaceutical
Danish diabetes giant Novo Nordisk’s recent share price rally continued on the news of positive results of the cardiovascular safety of Tresiba (insulin degludec) compared to insulin glargine U100 when added to standard of care. 30 November 2016
Pharmaceutical
The increasing demand for type 2 diabetes mellitus (T2DM) therapeutics, caused by rising prevalence of the disease, has resulted in a large and competitive market landscape. 29 November 2016
Pharmaceutical
Adding to US approval early last year for their combination diabetes product, German family-owned drug major Boehringer Ingelheim and USA-based Eli Lilly have received clearance to market it in Europe. 25 November 2016
Pharmaceutical
Japan is likely to see more than 20 new drugs from French pharma major Sanofi by 2020, said the newly-appointed Sanofi Japan chief executive Jacques Nathan at a press meeting held in Tokyo earlier this month. 25 November 2016
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s new drug application (NDA) for Xultophy (insulin degludec/liraglutide) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin or liraglutide. 22 November 2016
Pharmaceutical
The US Food and Drug Administration has approved the once-daily combination of insulin glargine and lixisenatide injection for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide. 22 November 2016
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze